Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
Author(s)
Type
Journal Article
Abstract
Whilst the majority of patients with COVID-19 infection have mild self-limiting symptoms, for some the SARS-CoV2 virus can trigger a severe hyperinflammatory syndrome which is life threatening. Anti-IL6 therapy has shown promise in restraining the hyperinflammatory syndrome and while IL-6 is a pleiotropic mediatory of the inflammatory response, redundancy within inflammatory pathways means that the use of such targeted monoclonal therapy may have too restricted a repertoire in some patients. We present the case of a 53-year-old haematopoetic stem cell transplant recipient who developed a severe COVID-19 that was refractory to anti-IL6 therapy, but responded to Jak-Stat inhibition with ruxolitinib, demonstrating its safety and efficacy in this setting.
Date Issued
2020-07-26
Date Acceptance
2020-06-01
ISSN
0007-1048
Publisher
Wiley
Start Page
e198
End Page
e200
Journal / Book Title
British Journal of Haematology
Volume
190
Issue
4
Copyright Statement
This article is protected by copyright. All rights reserved.
Identifier
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16979
https://www.ncbi.nlm.nih.gov/pubmed/32593183
Subjects
Science & Technology
Life Sciences & Biomedicine
Hematology
transplant
infection
COVID-19
immunosupression
COVID-19
immunosupression
infection
transplant
1102 Cardiorespiratory Medicine and Haematology
Immunology
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2020-06-27